Clinical trial · Interventional
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
NCT04322890CI-TRIAL-00081842PIKACHUrecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALK Gene Mutation | — | UNRESOLVED | — |
| EGFR Gene Mutation | — | UNRESOLVED | — |
| MET Gene Mutation | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| ROS1 Gene Mutation | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alectinib 150 MG | Drug | Alectinib | ALIAS |
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Crizotinib 250 MG | Drug | Crizotinib | ALIAS |
| Osimertinib | Drug | Osimertinib | ALIAS |
| Savolitinib, Crizotinib. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- EXPERIMENTAL
- label
- Cohort A: EGFR mutation
- description
- Lung Cancer with EGFR mutation including EGFR exon19del, exon 21L858R, etc.
- interventionNames
- Drug: Osimertinib
- type
- EXPERIMENTAL
- label
- Cohort B: ALK fusion
- description
- Lung Cancer with ALK fusion.
- interventionNames
- Drug: Alectinib 150 MG
- type
- EXPERIMENTAL
- label
- Cohort C: ROS1 fusion
- description
- Lung Cancer with ROS1 fusion.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. 2. Age ≥ 18 years. 3. Histologically or cytologically confirmed, Stage IV NSCLC. 4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc. 5. ECOG 0-1. 6. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1. Exclusion Criteria: The patient did not match from the Inclusion Criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.